R. Kaiko

发表

The effect of food intake on the pharmacokinetics of sustained-release morphine sulfate capsules.

R. Kaiko, 1997, Clinical therapeutics.

Clinical Pharmacokinetics of Controlled‐Release Oxycodone in Renal Impairment

D. Benziger, R. Kaiko, C. Cheng, 1996 .

Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.

J. Wild, R. Fleischmann, P. Lacouture, 1999, The Clinical journal of pain.

Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults.

T. Hunt, R. Kaiko, 1991, Clinical therapeutics.

Pharmacokinetic‐pharmacodynamic relationships of controlled‐release oxycodone

R. Reder, P. Goldenheim, R. Fitzmartin, 1996, Clinical pharmacology and therapeutics.

Cancer pain management with a controlled-release oral morphine preparation.

K. Foley, N. Coyle, R. Houde, 1989, Journal of pain and symptom management.

Controversy in the management of chronic cancer pain: therapeutic equivalents of IM and PO morphine.

R. Kaiko, 1986, Journal of pain and symptom management.

The United States experience with oral controlled‐release morphine (MS contin tablets).parts i and ii. review of nine dose titration studies and clinical pharmacology of 15‐mg, 30‐mg, 60‐mg, and 100‐mg tablet strengths in normal subjects

J. Pav, P. Goldenheim, R. Kaiko, 1989, Cancer.

Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.

M. Citron, W. Parris, B. Buckley, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Bioavailability of Morphine in Controlled‐Release 30‐mg Tablets per Rectum Compared With Immediate‐Release 30‐mg Rectal Suppositories and Controlled‐Release 30‐mg Oral Tablets

P. Goldenheim, R. Fitzmartin, R. Kaiko, 1992, Pharmacotherapy.

Controlled‐release oxycodone compared with controlled‐release morphine in the treatment of cancer pain: A randomized, double‐blind, parallel‐group study

M. Citron, S. Weinstein, B. Buckley, 1998, European journal of pain.

Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade.

R. Reder, P. Goldenheim, E. Bashaw, 1995, International journal of clinical pharmacology and therapeutics.

A Bioequivalence Study of Oral Controlled‐Release Morphine Using Naltrexone Blockade

R. Sackler, R. Reder, P. Goldenheim, 1995, Journal of clinical pharmacology.

Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.

D R Stanski, D. Stanski, J. Mandema, 2003, British journal of clinical pharmacology.

Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.

M. Chasin, R. Reder, R. Fitzmartin, 1996, Journal of pharmaceutical sciences.

The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study.

Benjamin W. Johnson, W. Parris, A. Khojasteh, 1998, Journal of pain and symptom management.

Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain.

M. Citron, W. Parris, R. Rosenbluth, 1998, Cancer investigation.

Pharmacokinetics and pharmacodynamics of controlled‐release opioids

R. Kaiko, 1997, Acta anaesthesiologica Scandinavica.

Oral controlled‐release morphine sulfate. Analgesic efficacy and side effects of a 100‐mg tablet in cancer pain patients

R. Portenoy, R. Kanner, R. Fitzmartin, 1989, Cancer.

Analgesic Efficacy of Controlled‐Release Oxycodone in Postoperative Pain

A. Sunshine, N. Olson, R. Reder, 1996, Journal of clinical pharmacology.

Age and morphine analgesia in cancer patients with postoperative pain.

R. Kaiko, 1981, Clinical pharmacology and therapeutics.

Steady-state bioavailability of controlled-release oxycodone in normal subjects.

R. Reder, R. Kaiko, J. Miotto, 1996, Clinical therapeutics.

Relative Variability in Bioavailability of Oral Controlled-Release Formulations of Oxycodone and Morphine

R. Colucci, R. Swanton, R. Kaiko, 2001, American journal of therapeutics.

Analgesic Onset and Potency of Oral Controlled‐Release (CR) Oxycodone and CR Morphine

P. Lacouture, J. Brown, R. Kaiko, 1996 .

Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food.

P. Goldenheim, C. Cronin, R. Kaiko, 1990, The Hospice Journal.

Analgesic efficacy and potency of two oral controlled‐release morphine preparations

Jeanette. Mitchell, T. Barden, S. Bloomfield, 1993, Clinical pharmacology and therapeutics.

The Therapeutic Equivalence of IM and PO Administration of Morphine – 1:3 or 1:6?

R. Kaiko, R. Kaiko, 1988, Journal of palliative care.

Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient

R. Kaiko, 1991 .

Steady-State Pharmacokinetics of Controlled Release Oral Morphine Sulphate in Healthy Subjects

J. Savarese, P. Goldenheim, R. Kaiko, 1986, Clinical pharmacokinetics.

A study of controlled-release oral morphine (MS Contin) in an advanced cancer hospital.

J. Savarese, F. Brescia, R. Kaiko, 1987, Journal of pain and symptom management.

A Double‐blind, Placebo‐Controlled, Repeated Dose, Dose‐Response Evaluation of Controlled‐Release (CR) Oxycodone in Patients with Osteoarthritis

P. Lacouture, S. Roth, R. Kaiko, 1996 .